tiprankstipranks
Advertisement
Advertisement

HK:2575 Stock Latest News

Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
Company AnnouncementsXuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
15d ago
2575
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
16d ago
2575
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
30d ago
2575
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
PremiumCompany Announcements
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
2M ago
2575
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
PremiumCompany Announcements
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
2M ago
2575
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
2M ago
2575
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
Premium
Company Announcements
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
2M ago
2575
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
Premium
Company Announcements
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
2M ago
2575
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
PremiumCompany Announcements
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
2M ago
2575
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
2M ago
2575
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
PremiumCompany Announcements
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
3M ago
2575
Xuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
PremiumCompany Announcements
Xuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
3M ago
2575
Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
3M ago
2575
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
Premium
Company Announcements
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
3M ago
2575
Xuanzhu Wins First-Line Breast Cancer Nod for Bireociclib, Extending Market Lead
Premium
Company Announcements
Xuanzhu Wins First-Line Breast Cancer Nod for Bireociclib, Extending Market Lead
3M ago
2575
Xuanzhu Biopharm Joins Hang Seng Composite Index, Eyes Broader Investor Base
PremiumCompany Announcements
Xuanzhu Biopharm Joins Hang Seng Composite Index, Eyes Broader Investor Base
4M ago
2575
Xuanzhu Biopharmaceutical Consolidates Leadership as Chairperson Xu Yanjun Becomes General Manager
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Consolidates Leadership as Chairperson Xu Yanjun Becomes General Manager
5M ago
2575
Xuanzhu Biopharmaceutical Details Board and Committee Composition
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Details Board and Committee Composition
5M ago
2575
Xuanzhu Biopharmaceutical Executive Director and General Manager Resigns
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Executive Director and General Manager Resigns
5M ago
2575
Xuanzhu Biopharmaceutical’s Anjiuwei Secures Spot in 2025 NRDL
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical’s Anjiuwei Secures Spot in 2025 NRDL
6M ago
2575
Xuanzhu Biopharmaceutical’s Drug Xuanyuening Gains National Reimbursement Approval
Premium
Company Announcements
Xuanzhu Biopharmaceutical’s Drug Xuanyuening Gains National Reimbursement Approval
6M ago
2575
Xuanzhu Biopharmaceutical Initiates Full Circulation of H Shares
Premium
Company Announcements
Xuanzhu Biopharmaceutical Initiates Full Circulation of H Shares
7M ago
2575

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >